

Olivier Thaunat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4142847/publications.pdf>

Version: 2024-02-01

93
papers

4,188
citations

101543

36
h-index

133252

59
g-index

121
all docs

121
docs citations

121
times ranked

4759
citing authors

#	ARTICLE	IF	CITATIONS
1	A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis. <i>Kidney International</i> , 2022, 101, 390-402.	5.2	72
2	Incidence of cytomegalovirus infection in seropositive kidney transplant recipients treated with everolimus: A randomized, open-label, multicenter phase 4 trial. <i>American Journal of Transplantation</i> , 2022, 22, 1430-1441.	4.7	5
3	Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series. <i>Annals of Internal Medicine</i> , 2022, 175, 455-456.	3.9	98
4	Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients. <i>Science Translational Medicine</i> , 2022, 14, eabl6141.	12.4	52
5	A comprehensive assessment of long-term SARS-CoV-2-specific adaptive immune memory in convalescent COVID-19 Solid Organ Transplant recipients. <i>Kidney International</i> , 2022, 101, 1027-1038.	5.2	10
6	Predictive factors of a viral neutralizing humoral response after a third dose of COVID-19 mRNA vaccine. <i>American Journal of Transplantation</i> , 2022, 22, 1442-1450.	4.7	15
7	Circulating Donor-Specific Anti-HLA Antibodies Associate With Immune Activation Independent of Kidney Transplant Histopathological Findings. <i>Frontiers in Immunology</i> , 2022, 13, 818569.	4.8	15
8	Low T Cell Responsiveness in the Early Phase of COVID-19 Associates with Progression to Severe Pneumonia in Kidney Transplant Recipients. <i>Viruses</i> , 2022, 14, 542.	3.3	3
9	Pretransplant endotrophin predicts delayed graft function after kidney transplantation. <i>Scientific Reports</i> , 2022, 12, 4079.	3.3	10
10	Early Administration of Anti-SARS-CoV-2 Monoclonal Antibodies Prevents Severe COVID-19 in Kidney Transplant Patients. <i>Kidney International Reports</i> , 2022, 7, 1241-1247.	0.8	25
11	Allorecognition and the spectrum of kidney transplant rejection. <i>Kidney International</i> , 2022, 101, 692-710.	5.2	65
12	Pre-exposure prophylaxis with 300 mg Evusheld elicits limited neutralizing activity against the Omicron variant. <i>Kidney International</i> , 2022, 102, 442-444.	5.2	34
13	Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients. <i>American Journal of Transplantation</i> , 2022, 22, 2675-2681.	4.7	48
14	Evolution of humoral lesions on follow-up biopsy stratifies the risk for renal graft loss after antibody-mediated rejection treatment. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2555-2568.	0.7	1
15	De Novo Complement-Binding Anti-HLA Antibodies in Heart Transplanted Patients Is Associated with Severe Cardiac Allograft Vasculopathy and Poor Long-Term Survival. <i>Journal of Clinical Medicine</i> , 2022, 11, 3731.	2.4	2
16	Microvascular inflammation: Gene expression changes do not necessarily reflect pathogenesis. <i>American Journal of Transplantation</i> , 2022, 22, 3180-3181.	4.7	2
17	Diagnostic performance of kSORT, a blood-based mRNA assay for noninvasive detection of rejection after kidney transplantation: A retrospective multicenter cohort study. <i>American Journal of Transplantation</i> , 2021, 21, 740-750.	4.7	22
18	Missing Self-Induced Activation of NK Cells Combines with Non-Complement-Fixing Donor-Specific Antibodies to Accelerate Kidney Transplant Loss in Chronic Antibody-Mediated Rejection. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 479-494.	6.1	56

#	ARTICLE	IF	CITATIONS
19	Is COVID-19 infection more severe in kidney transplant recipients?. American Journal of Transplantation, 2021, 21, 1295-1303.	4.7	190
20	Data-driven Derivation and Validation of Novel Phenotypes for Acute Kidney Transplant Rejection using Semi-supervised Clustering. Journal of the American Society of Nephrology: JASN, 2021, 32, 1084-1096.	6.1	28
21	The authors reply. Kidney International, 2021, 99, 771-772.	5.2	1
22	Revisiting the changes in the Banff classification for antibody-mediated rejection after kidney transplantation. American Journal of Transplantation, 2021, 21, 2413-2423.	4.7	34
23	Stratifying the humoral risk of candidates to a solid organ transplantation: a proposal of the ENGAGE working group. Transplant International, 2021, 34, 1005-1018.	1.6	23
24	SARS-CoV-2-specific serological and functional T cell immune responses during acute and early COVID-19 convalescence in solid organ transplant patients. American Journal of Transplantation, 2021, 21, 2749-2761.	4.7	46
25	Immunological Monitoring in Beta Cell Replacement: Towards a Pathophysiology-Guided Implementation of Biomarkers. Current Diabetes Reports, 2021, 21, 19.	4.2	5
26	Innate (and Innate-like) Lymphoid Cells: Emerging Immune Subsets With Multiple Roles Along Transplant Life. Transplantation, 2021, 105, e322-e336.	1.0	9
27	Prospective Measures of Adherence by Questionnaire, Low Immunosuppression and Graft Outcome in Kidney Transplantation. Journal of Clinical Medicine, 2021, 10, 2032.	2.4	3
28	Polyclonal expansion of TCR V β 21.3 ⁺ CD4 ⁺ and CD8 ⁺ T cells is a hallmark of multisystem inflammatory syndrome in children. Science Immunology, 2021, 6, .	11.9	105
29	Allograft recognition by recipient's natural killer cells: Molecular mechanisms and role in transplant rejection. Hla, 2021, 98, 191-199.	0.6	14
30	Missing Self-Induced Microvascular Rejection of Kidney Allografts: A Population-Based Study. Journal of the American Society of Nephrology: JASN, 2021, 32, 2070-2082.	6.1	38
31	Clinical Utility of Biochemical Markers for the Prediction of COVID-19-Related Mortality in Kidney Transplant Recipients. Kidney International Reports, 2021, 6, 2689-2693.	0.8	8
32	T α and B α cell therapy in solid organ transplantation: current evidence and future expectations. Transplant International, 2021, 34, 1594-1606.	1.6	1
33	Impact of Covid-19 on kidney transplant and waiting list patients: Lessons from the first wave of the pandemic. Nephrologie Et Therapeutique, 2021, 17, 245-251.	0.5	8
34	Occurrence of severe COVID-19 in vaccinated transplant patients. Kidney International, 2021, 100, 477-479.	5.2	101
35	COVID-19 vaccination in kidney transplant recipients. Nature Reviews Nephrology, 2021, 17, 785-787.	9.6	99
36	The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis. Kidney International, 2021, 100, 928-936.	5.2	61

#	ARTICLE	IF	CITATIONS
37	Humoral Alloreactivity in VCA Recipients: Should We Learn From Our Experience?. Transplantation, 2020, 104, 2003-2010.	1.0	6
38	Combined Liver-Kidney Transplantation With Preformed Anti-human Leukocyte Antigen Donor-Specific Antibodies. Kidney International Reports, 2020, 5, 2202-2211.	0.8	6
39	An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants. Kidney International, 2020, 98, 1549-1558.	5.2	213
40	IMPact of the COVID-19 epidemic on the moRTality of kidney transplant recipients and candidates in a French Nationwide registry sTudy (IMPORTANT). Kidney International, 2020, 98, 1568-1577.	5.2	85
41	Chronic Kidney Disease-Associated Immune Dysfunctions: Impact of Protein-Bound Uremic Retention Solutes on Immune Cells. Toxins, 2020, 12, 300.	3.4	66
42	Transcriptional Changes in Kidney Allografts with Histology of Antibody-Mediated Rejection without Anti-HLA Donor-Specific Antibodies. Journal of the American Society of Nephrology: JASN, 2020, 31, 2168-2183.	6.1	60
43	Performances of creatinine-based glomerular filtration rate estimating equations in simultaneous pancreas-kidney transplant recipients: a single center cohort study. Transplant International, 2019, 32, 75-83.	1.6	4
44	Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. BMJ: British Medical Journal, 2019, 366, l4923.	2.3	191
45	Highly Variable Sialylation Status of Donor-Specific Antibodies Does Not Impact Humoral Rejection Outcomes. Frontiers in Immunology, 2019, 10, 513.	4.8	11
46	Early Acute Microvascular Kidney Transplant Rejection in the Absence of Anti-HLA Antibodies Is Associated with Preformed IgG Antibodies against Diverse Glomerular Endothelial Cell Antigens. Journal of the American Society of Nephrology: JASN, 2019, 30, 692-709.	6.1	81
47	Pregnancy and donor-specific HLA-antibody-mediated rejection after liver transplantation: "Liaisons dangereuses". Transplant Immunology, 2019, 54, 47-51.	1.2	9
48	Missing self triggers NK cell-mediated chronic vascular rejection of solid organ transplants. Nature Communications, 2019, 10, 5350.	12.8	100
49	Natural killer cell infiltration is discriminative for antibody-mediated rejection and predicts outcome after kidney transplantation. Kidney International, 2019, 95, 188-198.	5.2	116
50	Infections after upper extremity allotransplantation: a worldwide population cohort study, 1998-2017. Transplant International, 2019, 32, 693-701.	1.6	12
51	Indications for islet or pancreatic transplantation: Statement of the TREPID working group on behalf of the Soci�t� francophone du diab�te (SFD), Soci�t� fran�aise d'endocrinologie (SFE), Soci�t� francophone de transplantation (SFT) and Soci�t� fran�aise de nephrologie "�dialyse" transplantation (SFNDT). Diabetes and Metabolism, 2019, 45, 224-237.	2.9	35
52	The disappointing contribution of anti-human leukocyte antigen donor-specific antibodies characteristics for predicting allograft loss. Nephrology Dialysis Transplantation, 2018, 33, 1853-1863.	0.7	30
53	Mechanisms underlying human genetic diversity: consequence for antigraft antibody responses. Transplant International, 2018, 31, 239-250.	1.6	15
54	FP697ACTIVABILITY OF CIRCULATING TFH17 PREDICTS HUMORAL RESPONSE TO THYMUS-DEPENDENT ANTIGENS. Nephrology Dialysis Transplantation, 2018, 33, i281-i281.	0.7	0

#	ARTICLE	IF	CITATIONS
55	CD4+ T Cell Help Is Mandatory for Naive and Memory Donor-Specific Antibody Responses: Impact of Therapeutic Immunosuppression. <i>Frontiers in Immunology</i> , 2018, 9, 275.	4.8	47
56	Residual Activatability of Circulating Tfh17 Predicts Humoral Response to Thymodependent Antigens in Patients on Therapeutic Immunosuppression. <i>Frontiers in Immunology</i> , 2018, 9, 3178.	4.8	16
57	Pregnancy outcomes in simultaneous pancreas and kidney transplant recipients: a national French survey study. <i>Transplant International</i> , 2017, 30, 893-902.	1.6	17
58	mTOR inhibitors and risk of chronic antibody-mediated rejection after kidney transplantation: where are we now?. <i>Transplant International</i> , 2017, 30, 647-657.	1.6	32
59	Computer-assisted topological analysis of renal allograft inflammation adds to risk evaluation at diagnosis of humoral rejection. <i>Kidney International</i> , 2017, 92, 214-226.	5.2	28
60	Hypothermic pulsatile preservation of kidneys from uncontrolled deceased donors after cardiac arrest - a retrospective study. <i>Transplant International</i> , 2017, 30, 1284-1291.	1.6	9
61	Endothelial chimerism and vascular sequestration protect pancreatic islet grafts from antibody-mediated rejection. <i>Journal of Clinical Investigation</i> , 2017, 128, 219-232.	8.2	37
62	High mTOR activity is a hallmark of reactive natural killer cells and amplifies early signaling through activating receptors. <i>ELife</i> , 2017, 6, .	6.0	65
63	Lymphoid Neogenesis and Tertiary Lymphoid Organs in Transplanted Organs. <i>Frontiers in Immunology</i> , 2016, 7, 646.	4.8	69
64	Capillary Thrombosis in the Skin. <i>Transplantation</i> , 2016, 100, 954-957.	1.0	30
65	B Cells and Antibodies in Transplantation. <i>Transplantation</i> , 2016, 100, 1460-1464.	1.0	14
66	Monitoring efficiency of humoral rejection episode therapy in liver transplantation: any role for complement binding Luminex Single Antigen assays?. <i>Transplant Immunology</i> , 2016, 35, 23-28.	1.2	9
67	Generation of Catalytic Antibodies Is an Intrinsic Property of an Individual's Immune System: A Study on a Large Cohort of Renal Transplant Patients. <i>Journal of Immunology</i> , 2016, 196, 4075-4081.	0.8	3
68	Alloimmune-induced intragraft lymphoid neogenesis promotes B-cell tolerance breakdown that accelerates chronic rejection. <i>Current Opinion in Organ Transplantation</i> , 2016, 21, 368-374.	1.6	15
69	An integrated view of immune monitoring in vascularized composite allotransplantation. <i>Current Opinion in Organ Transplantation</i> , 2016, 21, 516-522.	1.6	5
70	Chronic Rejection in Human Vascularized Composite Allotransplantation (Hand and Face Recipients). <i>Transplantation</i> , 2016, 100, 2053-2061.	1.0	73
71	Non-Complement-Binding De Novo Donor-Specific Anti-HLA Antibodies and Kidney Allograft Survival. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 615-625.	6.1	116
72	B Cells Loaded with Synthetic Particulate Antigens: A Versatile Platform To Generate Antigen-Specific Helper T Cells for Cell Therapy. <i>Nano Letters</i> , 2016, 16, 297-308.	9.1	12

#	ARTICLE	IF	CITATIONS
73	Effect of Immunosuppressive Drugs on Humoral Allosensitization after Kidney Transplant. Journal of the American Society of Nephrology: JASN, 2016, 27, 1890-1900.	6.1	47
74	Immunological Challenges in Vascularised Composite Allotransplantation. Current Transplantation Reports, 2015, 2, 276-283.	2.0	6
75	Clinicopathological Findings of Chronic Rejection in a Face Grafted Patient. Transplantation, 2015, 99, 2644-2650.	1.0	96
76	Immunopathology of rejection. Current Opinion in Organ Transplantation, 2015, 20, 596-601.	1.6	26
77	Finding the safe place between the hammer and the anvil: sounding the depth of therapeutic immunosuppression. Kidney International, 2015, 88, 1226-1228.	5.2	16
78	Recent advances in renal transplantation: antibody-mediated rejection takes center stage. F1000prime Reports, 2015, 7, 51.	5.9	44
79	Cell Therapy to Induce Allograft Tolerance: Time to Switch to Plan B?. Frontiers in Immunology, 2015, 6, 149.	4.8	12
80	Soothing touch of CD31 protects endothelium during cellular immune responses. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 13133-13134.	7.1	7
81	Detection of C3d-Binding Donor-Specific Anti-HLA Antibodies at Diagnosis of Humoral Rejection Predicts Renal Graft Loss. Journal of the American Society of Nephrology: JASN, 2015, 26, 457-467.	6.1	226
82	Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival. Kidney International, 2014, 85, 182-190.	5.2	35
83	Allotransplantation of kidney from unrelated living donor with loin pain haematuria syndrome. Transplant International, 2014, 27, e24-e26.	1.6	4
84	A stepwise breakdown of B-cell tolerance occurs within renal allografts during chronic rejection. Kidney International, 2012, 81, 207-219.	5.2	47
85	Humoral immunity in chronic allograft rejection: Puzzle pieces come together. Transplant Immunology, 2012, 26, 101-106.	1.2	55
86	Amâ€œBâ€œvalent: anti-CD20 antibodies unravel the dual role of B cells in immunopathogenesis. Blood, 2010, 116, 515-521.	1.4	60
87	Chronic humoral rejection mediated by anti-HLA-DP alloantibodies: Insights into the role of epitope sharing in donor-specific and non-donor specific alloantibodies generation. Transplant Immunology, 2009, 20, 209-211.	1.2	52
88	B Cell Survival in Intragraft Tertiary Lymphoid Organs After Rituximab Therapy. Transplantation, 2008, 85, 1648-1653.	1.0	125
89	Lymphoid neogenesis in chronic rejection. Current Opinion in Organ Transplantation, 2008, 13, 16-19.	1.6	33
90	Atheroprotective Effect of CD31 Receptor Globulin Through Enrichment of Circulating Regulatory T-Cells. Journal of the American College of Cardiology, 2007, 50, 344-350.	2.8	37

#	ARTICLE	IF	CITATIONS
91	Direct and Indirect Effects of Alloantibodies Link Neointimal and Medial Remodeling in Graft Arteriosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 2359-2365.	2.4	32
92	Lymphoid neogenesis in chronic rejection: Evidence for a local humoral alloimmune response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 14723-14728.	7.1	227
93	Alloimmune Risk Stratification for Kidney Transplant Rejection. <i>Transplant International</i> , 0, 35, .	1.6	10